26.00 -0.02 (-0.08%)
MYGN
Stock Details
Last Trade:26.00 Change:-0.02 (-0.08%) Prev Close:26.02 Open: 26.12 Days Range:25.88 – 26.80 52 Week Range: 25.70 - 89.84 Volume:5515110 P/E: 19.55EPS:1.33
View AllRecent Alerts 07/04/09
Recent Alert on 07/01/09 at 11:58am
Unusual 11 Mid-Day Movers 7/1: OSK, BORL, UIS, SDTH Higher; BEAT, FRPT, RPRX, SPAR Lower
Unusual 11 Mid-Day Movers 7/1: OSK, BORL, UIS, SDTH Higher; BEAT, FRPT, RPRX, SPAR Lower
CardioNet (Nasdaq: BEAT) 40.1% LOWER; sees FY09 sales of $156 million to $160 million, versus the consensus of $171.9 million. The revenue guidance is based on lower than anticipated commercial reimbursement rates. Volume growth continues to be... Read More
Recent Alert on 07/01/09 at 10:13am
Morgan Joseph Downgrades Myriad Genetics (MYGN) from Buy to Sell; Lowers Estimates
Morgan Joseph Downgrades Myriad Genetics (MYGN) from Buy to Sell; Lowers Estimates
Recent Alert on 07/01/09 at 9:39am
Notable Analyst Rating Changes 7/1: YUM, TRW, MGA, MVL Upgraded; FRPT, NDAQ, BEAT, MYGN Downgraded
Notable Analyst Rating Changes 7/1: YUM, TRW, MGA, MVL Upgraded; FRPT, NDAQ, BEAT, MYGN Downgraded
View AllRecent Press Releases
Press Release on 07/01/09 at 4:05pm
Myriad Genetics Announces Completion of Spin Off of Its Research and Pharmaceutical Business
Myriad Genetics Announces Completion of Spin Off of Its Research and Pharmaceutical Business
Press Release on 07/01/09 at 8:30am
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Press Release on 06/30/09 at 4:05pm
Myriad Genetics Announces Preliminary Revenue Results for Fiscal 2009 Fourth Quarter, Full Year
Myriad Genetics Announces Preliminary Revenue Results for Fiscal 2009 Fourth Quarter, Full Year
View AllRecent SEC Filings
No Recent SEC Filings Available